SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?


To: Don Miller who wrote (4263)3/9/2000 1:10:00 PM
From: rkrw  Read Replies (2) | Respond to of 10280
 
More important than hyping abstracts is getting drugs on the market. DCL will be the third drug approval for Sepracor. So while some (pitiable) investors long for hype, Sepracor continues building a formidable pipeline with powerful future earnings potential. By my count, Sepracor and its partners should be at around 10 drugs in the clinic.
norastemizole
ditropan
formoterol
meridia(+)
meridia(-)
zopiclone
prozac
propulsid
zyrtec
DCL
Xopenex-follow ons.



To: Don Miller who wrote (4263)3/9/2000 1:53:00 PM
From: jayhawk969  Read Replies (2) | Respond to of 10280
 
What level of risk is associated with the FTC approval? This appears to be a "biggy" either way.

J.D.